Mounjaro is an injectable medicine containing tirzepatide, which activates both GIP and GLP-1 receptors involved in appetite, fullness, blood glucose regulation and food intake. For eligible patients, it may be considered as part of a medically supervised weight-management plan.
Mounjaro is used once weekly according to a treatment plan determined by a doctor and is available in strengths from 2.5 mg to 15 mg.
A higher dose does not automatically mean better or faster weight loss. The appropriate dose depends on medical history, previous treatment, individual response and side effects.
Anyone considering Mounjaro should first be assessed for BMI, medical conditions, current medicines, treatment goals and individual risks.
Mounjaro is the brand name of a medicine containing tirzepatide, a single molecule that activates both GIP and GLP-1 receptors.
Tirzepatide is not a mixture of two hormones. It is one medicine designed to act on both receptor pathways.
These pathways are involved in:
Mounjaro does not directly burn or dissolve body fat. Weight-management treatment should therefore be supported by appropriate nutrition, physical activity, sleep and preservation of muscle mass.
Mounjaro may help some people feel less hungry, become full sooner and find it easier to control portion sizes, which can support a reduction in overall calorie intake.
Tirzepatide can also slow gastric emptying, particularly when treatment is started or the dose is increased.
Some patients may therefore notice:
However, having almost no appetite is not necessarily a sign of better treatment.
Eating too little may result in inadequate protein, fluid and nutrient intake. Medical follow-up should therefore assess more than body weight alone.
Other factors worth monitoring include:
In the SURMOUNT-1 clinical trial, participants receiving tirzepatide lost an average of approximately 15.0% to 20.9% of their starting body weight over 72 weeks, depending on dose and individual response.
| Study group | Average body-weight change at 72 weeks |
|---|---|
| Tirzepatide 5 mg | Approximately 15.0% reduction |
| Tirzepatide 10 mg | Approximately 19.5% reduction |
| Tirzepatide 15 mg | Approximately 20.9% reduction |
| Placebo | Approximately 3.1% reduction |
Participants in all study groups also received lifestyle guidance involving diet and physical activity.
These numbers are clinical-trial averages, not guaranteed results.
Actual weight change may be higher, lower or different from the study average depending on starting weight, health conditions, tolerated dose, treatment duration, diet, activity and side effects.
SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity or overweight who did not have type 2 diabetes. At 72 weeks, average body-weight reduction was approximately 20.2% with tirzepatide compared with 13.7% with semaglutide.
Because SURMOUNT-5 was a head-to-head trial, it provides a more direct comparison than comparing results from unrelated studies.
However, these findings do not mean tirzepatide is automatically the better medicine for every patient.
The choice of treatment should also consider:
There is no standard number of kilograms that everyone should lose during the first month of Mounjaro treatment.
The beginning of treatment is often focused on assessing tolerability and individual response rather than achieving the maximum possible weight reduction.
First-month weight change may depend on:
It would therefore be misleading to divide a 72-week clinical-trial result by the number of months and use that as a monthly target.
Weight loss does not usually occur at a constant rate throughout treatment.
Mounjaro is available in strengths ranging from 2.5 mg to 15 mg.
Available strengths include:
Different strengths allow doctors to adjust treatment according to response and tolerability.
Patients should not choose a strength based on body weight, the number of kilograms they want to lose or another person's treatment experience.
A higher dose is not automatically more appropriate.
Mounjaro prices at Smooth Clinic range from THB 12,900 to THB 26,500, depending on strength from 2.5 mg to 15 mg. The appropriate strength should be determined by a doctor rather than selected according to price.
| Mounjaro strength | Price |
|---|---|
| Mounjaro 2.5 mg | THB 12,900 |
| Mounjaro 5 mg | THB 14,900 |
| Mounjaro 7.5 mg | THB 17,900 |
| Mounjaro 10 mg | THB 21,500 |
| Mounjaro 12.5 mg | THB 25,000 |
| Mounjaro 15 mg | THB 26,500 |
Please confirm with the clinic whether the listed price refers to a KwikPen, box or treatment package, and whether doctor consultation, additional testing, supplies or follow-up are included.
Prices and product availability may change. Current information should be confirmed before booking or travelling to the clinic.
A higher-priced strength does not mean it will provide better results for every patient.
Mounjaro may be considered for adults with obesity or for adults who are overweight and have a related health condition, following an individual medical assessment.
Common weight-management criteria include:
Examples of weight-related conditions may include:
BMI is only one part of the medical assessment.
A doctor may also review:
Meeting a BMI threshold does not automatically mean that Mounjaro is appropriate.
People without diabetes may be considered for tirzepatide-based weight management when they meet relevant medical criteria and a doctor determines that the potential benefits outweigh the risks.
Both SURMOUNT-1 and SURMOUNT-5 studied tirzepatide in adults with obesity or overweight who did not have type 2 diabetes.
However, not having diabetes does not mean that anyone can start treatment.
Someone with a normal BMI who wants to lose a small amount of weight for cosmetic reasons may not match the populations studied in major obesity trials and may not be an appropriate candidate for medication.
The most common Mounjaro side effects involve the gastrointestinal system and may be more noticeable when treatment begins or after the dose is increased.
Possible symptoms include:
Symptoms may improve as the body adjusts.
However, patients should not increase the dose more quickly when they are still experiencing significant symptoms or are unable to eat or drink adequately.
Contact a doctor or clinic if you experience:
Persistent vomiting or diarrhoea can lead to dehydration and may affect kidney function.
Seek urgent medical assessment if you experience:
Do not wait for severe symptoms to resolve on their own.
People with certain medical conditions, those taking multiple medicines, and those who are pregnant or planning pregnancy should discuss their health history with a doctor before beginning Mounjaro.
Tell your doctor if you:
Mounjaro should not be combined with another tirzepatide product or another incretin-based medicine unless specifically directed by a doctor.
Weight regain can occur after tirzepatide is discontinued, particularly when there is no long-term weight-management strategy in place.
In SURMOUNT-4, participants who switched from tirzepatide to placebo after an initial treatment period regained an average of approximately 14.0% of body weight during the following 52 weeks.
Participants who continued tirzepatide lost an additional average of approximately 5.5%.
These are study averages.
They do not mean that everyone will regain the same amount of weight, nor do they mean that every patient must remain on treatment indefinitely.
Before reducing or stopping treatment, a longer-term plan should address:
Mounjaro contains tirzepatide, while Wegovy and Ozempic contain semaglutide. They are not the same medicine and should not be treated as interchangeable products.
| Product | Active ingredient | Main receptor activity |
|---|---|---|
| Mounjaro | Tirzepatide | GIP + GLP-1 |
| Wegovy | Semaglutide | GLP-1 |
| Ozempic | Semaglutide | GLP-1 |
| Saxenda | Liraglutide | GLP-1 |
Treatment should not be chosen simply because one medicine is described as “stronger” or because one trial reported a larger percentage of weight loss.
Approved indications, dose schedules, medical history, tolerability and individual treatment goals all matter.
Mounjaro may be an appropriate treatment option for some eligible patients, but whether it is suitable depends on the balance of benefits, risks, side effects, cost and long-term treatment goals.
Before starting treatment, consider five key questions:
The goal should not simply be to lose weight as quickly as possible.
A suitable plan should support weight reduction while maintaining overall health and long-term sustainability.
Mounjaro should be obtained through a healthcare setting or authorised supply channel where the source, product registration, packaging and storage conditions can be checked.
Injectable medicines require appropriate temperature control during transportation and storage.
A photograph of a box or injection pen posted online does not confirm that the product has been stored correctly throughout the supply chain.
Before receiving Mounjaro, check:
People interested in Mounjaro can begin with a medical assessment at Smooth Clinic to review health status, treatment goals, current medicines and individual suitability before treatment begins.
A typical process may include:
An appointment does not automatically mean that Mounjaro will be prescribed or that a requested strength will be provided.
Dose selection and treatment depend on the doctor's assessment.
Mounjaro is injected under the skin once a week according to the treatment plan prescribed by a doctor.
Patients should not increase the frequency or dose independently.
Mounjaro is administered as a subcutaneous injection, commonly in the abdomen, thigh or upper-arm area according to the instructions for the product supplied.
There is no single treatment duration that applies to everyone.
Duration depends on health goals, treatment response, side effects and the long-term weight-management plan.
Not necessarily.
Clinical trials have reported different average outcomes across dose groups, but higher doses may also affect tolerability and are not automatically suitable for every patient.
Not always.
If a person is unable to consume enough food, protein or fluids, nutritional status and muscle mass may be affected.
Very low food intake or persistent gastrointestinal symptoms should be discussed with a doctor.
Physical activity remains important for overall health and long-term weight management.
Resistance training may be particularly useful for supporting muscle preservation during weight loss when medically appropriate.
It may be considered for eligible patients who meet weight-management criteria.
Not having diabetes does not mean Mounjaro can be started without medical assessment.
Do not restart a previous dose independently after an extended treatment interruption.
A doctor should review how long treatment was stopped, the previous dose, treatment response and past side effects before deciding how to restart.
Contact Smooth Clinic to ask about current Mounjaro pricing, product availability and a medical assessment before beginning treatment.
Mounjaro prices currently range from THB 12,900 to THB 26,500 across strengths from 2.5 mg to 15 mg.
Ask About Mounjaro Prices and Availability Book a Doctor Assessment
An appointment does not guarantee that Mounjaro will be prescribed. Treatment eligibility, dose selection and follow-up depend on an individual medical assessment.
This information is provided for general educational purposes and does not replace medical diagnosis, treatment or advice from a doctor. Mounjaro eligibility, dose selection, treatment duration and follow-up depend on an individual medical assessment. Results and side effects may vary.
